Company Suda Pharmaceuticals Ltd Australian S.E.

Equities

SUD

AU0000063661

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote Australian S.E. Other stock markets			5-day change	1st Jan Change
- ^AUD	-.--%		-.--%	-.--%

Mar. 26	Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	MT
Mar. 20	Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	MT

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.

AUD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Development 100.0 %	0	100.0 %	0	100.0 %	+37.22%

AUD in Million	2022	Weight	2023	Weight	Delta
Australia 100.0 %	0	100.0 %	0	100.0 %	+37.22%

Managers	Title	Age	Since
Michael Baker CEO	Chief Executive Officer	-	20-01-01
Tim Luscombe DFI	Director of Finance/CFO	-	Nov. 30
Michelle Long ADM	Chief Administrative Officer	-	-
Nicole van der Weerden COO	Chief Operating Officer	-	23-01-03
Mini Bharathan PRN	Corporate Officer/Principal	-	22-01-31
Deborah Cooper PRN	Corporate Officer/Principal	-	-
Phillip Hains SEC	Corporate Secretary	64	20-06-30

Members of the board	Title	Age	Since
Gary Phillips BRD	Director/Board Member	62	22-06-30
Elizabeth Stoner BRD	Director/Board Member	73	21-11-09
Thomas Duthy CHM	Chairman	-	23-03-12
Michael Baker CEO	Chief Executive Officer	-	20-01-01
Debora Barton BRD	Director/Board Member	48	21-08-09

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	909,628,062	831,895,931 ( 91.45 %)	0	91.45 %

Name	Equities	%	Valuation
ESR-LOGOS REIT 6.889 %	63,735,605	6.889 %	6 M $
Mann Beef Pty Ltd. 5.502 %	50,905,657	5.502 %	5 M $
Blackburne Capital Pty Ltd. 2.073 %	19,175,000	2.073 %	2 M $
Dylide Pty Ltd. 1.693 %	15,666,666	1.693 %	2 M $
M & M Stock One Pty Ltd. 1.211 %	11,201,081	1.211 %	1 M $
Kamala Holdings Pty Ltd. 1.124 %	10,394,286	1.124 %	1 M $
Neil Donald Delroy 1.116 %	10,322,222	1.116 %	1 M $
Moovnup Pty Ltd. 1.097 %	10,145,462	1.097 %	992 835 $
Clive Jones 1.096 %	10,140,789	1.096 %	992 378 $
Brendan John Martin 1.034 %	9,564,970	1.034 %	936 028 $

Arovella Therapeutics Ltd.

62 Lygon Street Level 3, Suite 1

3053, Carlton South

+61 3 9863 6472

http://www.arovella.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research